Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Salgia

Showing results (441-450 of 529) with videos related to

Pageof 53
Sort By:
Cancer|September 16, 2024
Smoking prevalence and association with sociodemographic variables in cancer clinical trial participantsCary A Presant, Cathee Till, Riha Vaidya, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancerSai-Hong Ignatius Ou, Lyudmila Bazhenova, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2011
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cellsAna R Jensen, Saito Y David, Chuanhong Liao, et al.
Journal of Clinical Medicine|October 23, 2019
Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRASArjun Kalvala, Pierre Wallet, Lu Yang, et al.
BMC Cancer|January 7, 2014
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancerMichael L Maitland, Matthew R Levine, Mario E Lacouture, et al.
Cancer Research|March 26, 2009
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinomaTanguy Y Seiwert, Ramasamy Jagadeeswaran, Leonardo Faoro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinomaJennifer R Diamond, Ravi Salgia, Marileila Varella-Garcia, et al.
Future Science OA|January 13, 2021
Co-stimulatory and co-inhibitory immune markers in solid tumors with <i>MET</i> alterationsKaren L Reckamp, Jasmine A McQuerry, Isa Mambetsariev, et al.
Iscience|September 18, 2020
A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung CancerAtish Mohanty, Arin Nam, Alex Pozhitkov, et al.
Journal for Immunotherapy of Cancer|July 29, 2024
Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategiesAtish Mohanty, Michelle Afkhami, Amanda Reyes, et al.
Pageof 53

Showing results (441-450 of 529) with videos related to

Sort By:
Pageof 53
Cancer|September 16, 2024
Smoking prevalence and association with sociodemographic variables in cancer clinical trial participantsCary A Presant, Cathee Till, Riha Vaidya, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancerSai-Hong Ignatius Ou, Lyudmila Bazhenova, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2011
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cellsAna R Jensen, Saito Y David, Chuanhong Liao, et al.
Journal of Clinical Medicine|October 23, 2019
Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRASArjun Kalvala, Pierre Wallet, Lu Yang, et al.
BMC Cancer|January 7, 2014
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancerMichael L Maitland, Matthew R Levine, Mario E Lacouture, et al.
Cancer Research|March 26, 2009
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinomaTanguy Y Seiwert, Ramasamy Jagadeeswaran, Leonardo Faoro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinomaJennifer R Diamond, Ravi Salgia, Marileila Varella-Garcia, et al.
Future Science OA|January 13, 2021
Co-stimulatory and co-inhibitory immune markers in solid tumors with <i>MET</i> alterationsKaren L Reckamp, Jasmine A McQuerry, Isa Mambetsariev, et al.
Iscience|September 18, 2020
A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung CancerAtish Mohanty, Arin Nam, Alex Pozhitkov, et al.
Journal for Immunotherapy of Cancer|July 29, 2024
Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategiesAtish Mohanty, Michelle Afkhami, Amanda Reyes, et al.
Pageof 53